Evaluation of the quality of clinical data collection for a pan-Canadian cohort of children affected by inherited metabolic diseases: lessons learned from the Canadian Inherited Metabolic Diseases Research Network.
Data quality
Database
Inherited metabolic diseases
Observational research
Registry science
Sustainability
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
10 04 2020
10 04 2020
Historique:
received:
09
12
2019
accepted:
17
03
2020
entrez:
12
4
2020
pubmed:
12
4
2020
medline:
22
6
2021
Statut:
epublish
Résumé
The Canadian Inherited Metabolic Diseases Research Network (CIMDRN) is a pan-Canadian practice-based research network of 14 Hereditary Metabolic Disease Treatment Centres and over 50 investigators. CIMDRN aims to develop evidence to improve health outcomes for children with inherited metabolic diseases (IMD). We describe the development of our clinical data collection platform, discuss our data quality management plan, and present the findings to date from our data quality assessment, highlighting key lessons that can serve as a resource for future clinical research initiatives relating to rare diseases. At participating centres, children born from 2006 to 2015 who were diagnosed with one of 31 targeted IMD were eligible to participate in CIMDRN's clinical research stream. For all participants, we collected a minimum data set that includes information about demographics and diagnosis. For children with five prioritized IMD, we collected longitudinal data including interventions, clinical outcomes, and indicators of disease management. The data quality management plan included: design of user-friendly and intuitive clinical data collection forms; validation measures at point of data entry, designed to minimize data entry errors; regular communications with each CIMDRN site; and routine review of aggregate data. As of June 2019, CIMDRN has enrolled 798 participants of whom 764 (96%) have complete minimum data set information. Results from our data quality assessment revealed that potential data quality issues were related to interpretation of definitions of some variables, participants who transferred care across institutions, and the organization of information within the patient charts (e.g., neuropsychological test results). Little information was missing regarding disease ascertainment and diagnosis (e.g., ascertainment method - 0% missing). Using several data quality management strategies, we have established a comprehensive clinical database that provides information about care and outcomes for Canadian children affected by IMD. We describe quality issues and lessons for consideration in future clinical research initiatives for rare diseases, including accurately accommodating different clinic workflows and balancing comprehensiveness of data collection with available resources. Integrating data collection within clinical care, leveraging electronic medical records, and implementing core outcome sets will be essential for achieving sustainability.
Sections du résumé
BACKGROUND
The Canadian Inherited Metabolic Diseases Research Network (CIMDRN) is a pan-Canadian practice-based research network of 14 Hereditary Metabolic Disease Treatment Centres and over 50 investigators. CIMDRN aims to develop evidence to improve health outcomes for children with inherited metabolic diseases (IMD). We describe the development of our clinical data collection platform, discuss our data quality management plan, and present the findings to date from our data quality assessment, highlighting key lessons that can serve as a resource for future clinical research initiatives relating to rare diseases.
METHODS
At participating centres, children born from 2006 to 2015 who were diagnosed with one of 31 targeted IMD were eligible to participate in CIMDRN's clinical research stream. For all participants, we collected a minimum data set that includes information about demographics and diagnosis. For children with five prioritized IMD, we collected longitudinal data including interventions, clinical outcomes, and indicators of disease management. The data quality management plan included: design of user-friendly and intuitive clinical data collection forms; validation measures at point of data entry, designed to minimize data entry errors; regular communications with each CIMDRN site; and routine review of aggregate data.
RESULTS
As of June 2019, CIMDRN has enrolled 798 participants of whom 764 (96%) have complete minimum data set information. Results from our data quality assessment revealed that potential data quality issues were related to interpretation of definitions of some variables, participants who transferred care across institutions, and the organization of information within the patient charts (e.g., neuropsychological test results). Little information was missing regarding disease ascertainment and diagnosis (e.g., ascertainment method - 0% missing).
DISCUSSION
Using several data quality management strategies, we have established a comprehensive clinical database that provides information about care and outcomes for Canadian children affected by IMD. We describe quality issues and lessons for consideration in future clinical research initiatives for rare diseases, including accurately accommodating different clinic workflows and balancing comprehensiveness of data collection with available resources. Integrating data collection within clinical care, leveraging electronic medical records, and implementing core outcome sets will be essential for achieving sustainability.
Identifiants
pubmed: 32276663
doi: 10.1186/s13023-020-01358-z
pii: 10.1186/s13023-020-01358-z
pmc: PMC7149838
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
89Subventions
Organisme : CIHR
ID : TR3-119195
Pays : Canada
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Trials. 2012 Aug 06;13:132
pubmed: 22867278
J Clin Epidemiol. 2001 Jun;54(6):541-9
pubmed: 11377113
Genet Med. 2016 Dec;18(12):1276-1281
pubmed: 27195819
Genet Med. 2010 Dec;12(12 Suppl):S215-9
pubmed: 21150367
Genet Med. 2016 Aug 25;:
pubmed: 27561085
J Child Neurol. 2013 Sep;28(9):1142-50
pubmed: 24014509
J Glob Health. 2018 Dec;8(2):021102
pubmed: 30479748
Genet Med. 2019 Jan;21(1):102-106
pubmed: 29884839
Mol Genet Metab. 2010;100 Suppl 1:S97-105
pubmed: 20188616
Genet Med. 2019 Jun;21(6):1271-1279
pubmed: 30393376
Haemophilia. 2014 Jul;20(4):e280-6
pubmed: 24784937
Lancet. 2008 Jun 14;371(9629):2039-41
pubmed: 18555915
J Can Acad Child Adolesc Psychiatry. 2006 Aug;15(3):126-34
pubmed: 18392182
Genet Med. 2013 Jun;15(6):415-22
pubmed: 23222662
J Educ Eval Health Prof. 2013 Nov 30;10:12
pubmed: 24324853
Orphanet J Rare Dis. 2014 Jun 07;9:81
pubmed: 24908055
Genet Med. 2016 Feb;18(2):117-23
pubmed: 25856667
Adv Exp Med Biol. 2010;686:87-104
pubmed: 20824441
Orphanet J Rare Dis. 2018 Jun 28;13(1):104
pubmed: 29954425
N Engl J Med. 2013 Oct 24;369(17):1579-81
pubmed: 23991657
Nucleic Acids Res. 2019 Jan 8;47(D1):D1018-D1027
pubmed: 30476213
Can J Neurol Sci. 2013 Jul;40(4 Suppl 2):S1-3
pubmed: 23787261
Adv Exp Med Biol. 2017;1031:149-164
pubmed: 29214570
Int J Environ Res Public Health. 2018 Aug 03;15(8):
pubmed: 30081484
J Clin Epidemiol. 2016 Dec;80:16-24
pubmed: 27555082
JAMA Pediatr. 2015 Aug;169(8):778-82
pubmed: 26075348